nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—Homicidal ideation—Varenicline—nicotine dependence	0.0334	0.0487	CcSEcCtD
Paroxetine—Night blindness—Varenicline—nicotine dependence	0.0178	0.0259	CcSEcCtD
Paroxetine—Restless legs syndrome—Varenicline—nicotine dependence	0.0147	0.0214	CcSEcCtD
Paroxetine—Varicose vein—Varenicline—nicotine dependence	0.0112	0.0164	CcSEcCtD
Paroxetine—Pancreatitis acute—Varenicline—nicotine dependence	0.00907	0.0132	CcSEcCtD
Paroxetine—Aphthous stomatitis—Varenicline—nicotine dependence	0.00893	0.013	CcSEcCtD
Paroxetine—Myositis—Varenicline—nicotine dependence	0.00854	0.0125	CcSEcCtD
Paroxetine—Drug withdrawal syndrome—Varenicline—nicotine dependence	0.00854	0.0125	CcSEcCtD
Paroxetine—Peripheral vascular disorder—Varenicline—nicotine dependence	0.00854	0.0125	CcSEcCtD
Paroxetine—Extrapyramidal symptoms—Varenicline—nicotine dependence	0.00807	0.0118	CcSEcCtD
Paroxetine—Urine abnormality—Varenicline—nicotine dependence	0.00757	0.011	CcSEcCtD
Paroxetine—Hostility—Varenicline—nicotine dependence	0.00757	0.011	CcSEcCtD
Paroxetine—Osteoporosis—Varenicline—nicotine dependence	0.00747	0.0109	CcSEcCtD
Paroxetine—Sexual dysfunction—Varenicline—nicotine dependence	0.00747	0.0109	CcSEcCtD
Paroxetine—Sleep disturbance—Varenicline—nicotine dependence	0.00747	0.0109	CcSEcCtD
Paroxetine—Suicide attempt—Varenicline—nicotine dependence	0.00738	0.0108	CcSEcCtD
Paroxetine—Gastric ulcer—Varenicline—nicotine dependence	0.00721	0.0105	CcSEcCtD
Paroxetine—Urine analysis abnormal—Varenicline—nicotine dependence	0.00712	0.0104	CcSEcCtD
Paroxetine—Toothache—Varenicline—nicotine dependence	0.00689	0.01	CcSEcCtD
Paroxetine—Vaginal discharge—Varenicline—nicotine dependence	0.00689	0.01	CcSEcCtD
Paroxetine—Libido increased—Varenicline—nicotine dependence	0.00689	0.01	CcSEcCtD
Paroxetine—Parosmia—Varenicline—nicotine dependence	0.00646	0.00942	CcSEcCtD
Paroxetine—Electrocardiogram abnormal—Varenicline—nicotine dependence	0.00639	0.00932	CcSEcCtD
Paroxetine—Menstrual disorder—Varenicline—nicotine dependence	0.00615	0.00896	CcSEcCtD
Paroxetine—Intestinal obstruction—Varenicline—nicotine dependence	0.00615	0.00896	CcSEcCtD
Paroxetine—Paranoia—Varenicline—nicotine dependence	0.00615	0.00896	CcSEcCtD
Paroxetine—Haematemesis—Varenicline—nicotine dependence	0.00603	0.00879	CcSEcCtD
Paroxetine—Suicidal ideation—Varenicline—nicotine dependence	0.00597	0.00871	CcSEcCtD
Paroxetine—Thrombosis—Varenicline—nicotine dependence	0.00592	0.00863	CcSEcCtD
Paroxetine—Delusion—Varenicline—nicotine dependence	0.00592	0.00863	CcSEcCtD
Paroxetine—Nystagmus—Varenicline—nicotine dependence	0.00586	0.00855	CcSEcCtD
Paroxetine—Mania—Varenicline—nicotine dependence	0.00576	0.0084	CcSEcCtD
Paroxetine—Menorrhagia—Varenicline—nicotine dependence	0.00566	0.00825	CcSEcCtD
Paroxetine—Extrapyramidal disorder—Varenicline—nicotine dependence	0.00556	0.00811	CcSEcCtD
Paroxetine—Scotoma—Varenicline—nicotine dependence	0.00552	0.00804	CcSEcCtD
Paroxetine—Gingivitis—Varenicline—nicotine dependence	0.00534	0.00778	CcSEcCtD
Paroxetine—Mydriasis—Varenicline—nicotine dependence	0.00525	0.00766	CcSEcCtD
Paroxetine—Nephrolithiasis—Varenicline—nicotine dependence	0.00521	0.0076	CcSEcCtD
Paroxetine—Dysphonia—Varenicline—nicotine dependence	0.00509	0.00743	CcSEcCtD
Paroxetine—Endocrine disorder—Varenicline—nicotine dependence	0.00505	0.00737	CcSEcCtD
Paroxetine—Acne—Varenicline—nicotine dependence	0.00498	0.00726	CcSEcCtD
Paroxetine—Disturbance in attention—Varenicline—nicotine dependence	0.00484	0.00705	CcSEcCtD
Paroxetine—Aggression—Varenicline—nicotine dependence	0.00477	0.00695	CcSEcCtD
Paroxetine—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00464	0.00676	CcSEcCtD
Paroxetine—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.00464	0.00676	CcSEcCtD
Paroxetine—Thinking abnormal—Varenicline—nicotine dependence	0.00458	0.00667	CcSEcCtD
Paroxetine—Nocturia—Varenicline—nicotine dependence	0.00452	0.00659	CcSEcCtD
Paroxetine—Leukocytosis—Varenicline—nicotine dependence	0.00446	0.0065	CcSEcCtD
Paroxetine—Dysarthria—Varenicline—nicotine dependence	0.00443	0.00646	CcSEcCtD
Paroxetine—Coordination abnormal—Varenicline—nicotine dependence	0.00427	0.00622	CcSEcCtD
Paroxetine—Pulmonary embolism—Varenicline—nicotine dependence	0.00419	0.00611	CcSEcCtD
Paroxetine—Abnormal dreams—Varenicline—nicotine dependence	0.00414	0.00604	CcSEcCtD
Paroxetine—Eructation—Varenicline—nicotine dependence	0.00412	0.006	CcSEcCtD
Paroxetine—Hyperkalaemia—Varenicline—nicotine dependence	0.00412	0.006	CcSEcCtD
Paroxetine—Salivary hypersecretion—Varenicline—nicotine dependence	0.00407	0.00593	CcSEcCtD
Paroxetine—Nightmare—Varenicline—nicotine dependence	0.00404	0.0059	CcSEcCtD
Paroxetine—Photophobia—Varenicline—nicotine dependence	0.00393	0.00574	CcSEcCtD
Paroxetine—Oesophagitis—Varenicline—nicotine dependence	0.00383	0.00558	CcSEcCtD
Paroxetine—Urine output increased—Varenicline—nicotine dependence	0.00379	0.00552	CcSEcCtD
Paroxetine—Mouth ulceration—Varenicline—nicotine dependence	0.00379	0.00552	CcSEcCtD
Paroxetine—Hypertonia—Varenicline—nicotine dependence	0.00367	0.00535	CcSEcCtD
Paroxetine—Mental disability—Varenicline—nicotine dependence	0.00363	0.0053	CcSEcCtD
Paroxetine—Euphoric mood—Varenicline—nicotine dependence	0.0036	0.00525	CcSEcCtD
Paroxetine—Lymphadenopathy—Varenicline—nicotine dependence	0.00356	0.0052	CcSEcCtD
Paroxetine—Sleep disorder—Varenicline—nicotine dependence	0.00351	0.00512	CcSEcCtD
Paroxetine—Diabetes mellitus—Varenicline—nicotine dependence	0.0035	0.0051	CcSEcCtD
Paroxetine—Polyuria—Varenicline—nicotine dependence	0.00346	0.00505	CcSEcCtD
Paroxetine—Disorientation—Varenicline—nicotine dependence	0.0034	0.00496	CcSEcCtD
Paroxetine—Deafness—Varenicline—nicotine dependence	0.0034	0.00496	CcSEcCtD
Paroxetine—Eczema—Varenicline—nicotine dependence	0.00338	0.00493	CcSEcCtD
Paroxetine—Eye pain—Varenicline—nicotine dependence	0.00337	0.00491	CcSEcCtD
Paroxetine—CHRM4—Monoamine GPCRs—DRD2—nicotine dependence	0.00332	0.012	CbGpPWpGaD
Paroxetine—Injury—Varenicline—nicotine dependence	0.00331	0.00482	CcSEcCtD
Paroxetine—Renal failure acute—Varenicline—nicotine dependence	0.00329	0.0048	CcSEcCtD
Paroxetine—Libido decreased—Varenicline—nicotine dependence	0.00328	0.00478	CcSEcCtD
Paroxetine—Amnesia—Varenicline—nicotine dependence	0.00324	0.00472	CcSEcCtD
Paroxetine—Increased appetite—Varenicline—nicotine dependence	0.00324	0.00472	CcSEcCtD
Paroxetine—Atrial fibrillation—Varenicline—nicotine dependence	0.00321	0.00468	CcSEcCtD
Paroxetine—Visual disturbance—Varenicline—nicotine dependence	0.00321	0.00468	CcSEcCtD
Paroxetine—Thirst—Varenicline—nicotine dependence	0.00319	0.00466	CcSEcCtD
Paroxetine—CHRM5—Monoamine GPCRs—DRD2—nicotine dependence	0.00318	0.0115	CbGpPWpGaD
Paroxetine—Arthritis—Varenicline—nicotine dependence	0.00313	0.00456	CcSEcCtD
Paroxetine—Hypoglycaemia—Varenicline—nicotine dependence	0.00312	0.00454	CcSEcCtD
Paroxetine—Lethargy—Varenicline—nicotine dependence	0.0031	0.00453	CcSEcCtD
Paroxetine—Cerebrovascular accident—Varenicline—nicotine dependence	0.0031	0.00453	CcSEcCtD
Paroxetine—Osteoarthritis—Varenicline—nicotine dependence	0.00304	0.00443	CcSEcCtD
Paroxetine—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00304	0.00443	CcSEcCtD
Paroxetine—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.00302	0.0044	CcSEcCtD
Paroxetine—Migraine—Varenicline—nicotine dependence	0.00299	0.00436	CcSEcCtD
Paroxetine—Affect lability—Varenicline—nicotine dependence	0.00299	0.00436	CcSEcCtD
Paroxetine—TACR1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00299	0.0108	CbGpPWpGaD
Paroxetine—Psychotic disorder—Varenicline—nicotine dependence	0.00297	0.00433	CcSEcCtD
Paroxetine—CHRM2—cardiovascular system—nicotine dependence	0.00293	0.08	CbGeAlD
Paroxetine—Urinary retention—Varenicline—nicotine dependence	0.00289	0.00422	CcSEcCtD
Paroxetine—Mood swings—Varenicline—nicotine dependence	0.00288	0.0042	CcSEcCtD
Paroxetine—TACR1—brain—nicotine dependence	0.00285	0.0778	CbGeAlD
Paroxetine—TACR1—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00282	0.0102	CbGpPWpGaD
Paroxetine—Liver function test abnormal—Varenicline—nicotine dependence	0.00281	0.00409	CcSEcCtD
Paroxetine—CHRM4—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00279	0.0101	CbGpPWpGaD
Paroxetine—Dry skin—Varenicline—nicotine dependence	0.00279	0.00406	CcSEcCtD
Paroxetine—Hypokalaemia—Varenicline—nicotine dependence	0.00277	0.00404	CcSEcCtD
Paroxetine—Breast disorder—Varenicline—nicotine dependence	0.00275	0.00401	CcSEcCtD
Paroxetine—Cramp muscle—Varenicline—nicotine dependence	0.00274	0.00399	CcSEcCtD
Paroxetine—Nasopharyngitis—Varenicline—nicotine dependence	0.00272	0.00397	CcSEcCtD
Paroxetine—Gastritis—Varenicline—nicotine dependence	0.00269	0.00392	CcSEcCtD
Paroxetine—CHRM4—brain—nicotine dependence	0.00268	0.0732	CbGeAlD
Paroxetine—CHRM5—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00267	0.00963	CbGpPWpGaD
Paroxetine—CHRM1—cardiovascular system—nicotine dependence	0.00267	0.0728	CbGeAlD
Paroxetine—Dysphagia—Varenicline—nicotine dependence	0.00263	0.00383	CcSEcCtD
Paroxetine—Asthma—Varenicline—nicotine dependence	0.00263	0.00383	CcSEcCtD
Paroxetine—TACR1—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00256	0.00923	CbGpPWpGaD
Paroxetine—CHRM4—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00256	0.00922	CbGpPWpGaD
Paroxetine—Angina pectoris—Varenicline—nicotine dependence	0.00256	0.00373	CcSEcCtD
Paroxetine—Bronchitis—Varenicline—nicotine dependence	0.00253	0.00369	CcSEcCtD
Paroxetine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00252	0.00906	CbGpPWpGaD
Paroxetine—CYP2B6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00248	0.00895	CbGpPWpGaD
Paroxetine—TACR1—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00247	0.00888	CbGpPWpGaD
Paroxetine—CHRM5—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00245	0.00883	CbGpPWpGaD
Paroxetine—Pollakiuria—Varenicline—nicotine dependence	0.00243	0.00354	CcSEcCtD
Paroxetine—Erectile dysfunction—Varenicline—nicotine dependence	0.00242	0.00353	CcSEcCtD
Paroxetine—Photosensitivity reaction—Varenicline—nicotine dependence	0.0024	0.0035	CcSEcCtD
Paroxetine—Weight increased—Varenicline—nicotine dependence	0.00239	0.00349	CcSEcCtD
Paroxetine—Hyperglycaemia—Varenicline—nicotine dependence	0.00237	0.00346	CcSEcCtD
Paroxetine—Depression—Varenicline—nicotine dependence	0.00234	0.00341	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.00232	0.00339	CcSEcCtD
Paroxetine—Acute coronary syndrome—Varenicline—nicotine dependence	0.00231	0.00337	CcSEcCtD
Paroxetine—Myocardial infarction—Varenicline—nicotine dependence	0.0023	0.00335	CcSEcCtD
Paroxetine—Stomatitis—Varenicline—nicotine dependence	0.00228	0.00333	CcSEcCtD
Paroxetine—SLC6A3—midbrain—nicotine dependence	0.00228	0.0623	CbGeAlD
Paroxetine—Conjunctivitis—Varenicline—nicotine dependence	0.00228	0.00332	CcSEcCtD
Paroxetine—CHRM4—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00227	0.00816	CbGpPWpGaD
Paroxetine—HTR2A—Monoamine GPCRs—DRD2—nicotine dependence	0.00225	0.00811	CbGpPWpGaD
Paroxetine—CHRM1—Monoamine GPCRs—DRD2—nicotine dependence	0.00224	0.00807	CbGpPWpGaD
Paroxetine—CHRM3—Monoamine GPCRs—DRD2—nicotine dependence	0.00223	0.00804	CbGpPWpGaD
Paroxetine—Hepatobiliary disease—Varenicline—nicotine dependence	0.00222	0.00323	CcSEcCtD
Paroxetine—CHRM2—Monoamine GPCRs—DRD2—nicotine dependence	0.00221	0.00796	CbGpPWpGaD
Paroxetine—Epistaxis—Varenicline—nicotine dependence	0.00221	0.00322	CcSEcCtD
Paroxetine—Sinusitis—Varenicline—nicotine dependence	0.0022	0.00321	CcSEcCtD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00219	0.00788	CbGpPWpGaD
Paroxetine—Bradycardia—Varenicline—nicotine dependence	0.00214	0.00312	CcSEcCtD
Paroxetine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00213	0.00767	CbGpPWpGaD
Paroxetine—CYP2C8—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.0021	0.00757	CbGpPWpGaD
Paroxetine—CHRM5—brain—nicotine dependence	0.00209	0.0572	CbGeAlD
Paroxetine—Hallucination—Varenicline—nicotine dependence	0.00209	0.00305	CcSEcCtD
Paroxetine—Hypoaesthesia—Varenicline—nicotine dependence	0.00209	0.00305	CcSEcCtD
Paroxetine—SLC6A4—midbrain—nicotine dependence	0.00209	0.0571	CbGeAlD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00208	0.00749	CbGpPWpGaD
Paroxetine—Oedema peripheral—Varenicline—nicotine dependence	0.00207	0.00302	CcSEcCtD
Paroxetine—Connective tissue disorder—Varenicline—nicotine dependence	0.00207	0.00301	CcSEcCtD
Paroxetine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00204	0.00735	CbGpPWpGaD
Paroxetine—Visual impairment—Varenicline—nicotine dependence	0.00203	0.00296	CcSEcCtD
Paroxetine—Erythema multiforme—Varenicline—nicotine dependence	0.00199	0.0029	CcSEcCtD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00197	0.0071	CbGpPWpGaD
Paroxetine—Eye disorder—Varenicline—nicotine dependence	0.00197	0.00287	CcSEcCtD
Paroxetine—Tinnitus—Varenicline—nicotine dependence	0.00196	0.00286	CcSEcCtD
Paroxetine—Cardiac disorder—Varenicline—nicotine dependence	0.00195	0.00285	CcSEcCtD
Paroxetine—Angiopathy—Varenicline—nicotine dependence	0.00191	0.00278	CcSEcCtD
Paroxetine—Immune system disorder—Varenicline—nicotine dependence	0.0019	0.00277	CcSEcCtD
Paroxetine—Mediastinal disorder—Varenicline—nicotine dependence	0.0019	0.00276	CcSEcCtD
Paroxetine—HTR2A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00189	0.00682	CbGpPWpGaD
Paroxetine—Chills—Varenicline—nicotine dependence	0.00189	0.00275	CcSEcCtD
Paroxetine—CHRM1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00188	0.00678	CbGpPWpGaD
Paroxetine—Arrhythmia—Varenicline—nicotine dependence	0.00188	0.00274	CcSEcCtD
Paroxetine—CHRM3—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00188	0.00676	CbGpPWpGaD
Paroxetine—CHRM2—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00186	0.00669	CbGpPWpGaD
Paroxetine—Mental disorder—Varenicline—nicotine dependence	0.00184	0.00269	CcSEcCtD
Paroxetine—Malnutrition—Varenicline—nicotine dependence	0.00183	0.00267	CcSEcCtD
Paroxetine—Erythema—Varenicline—nicotine dependence	0.00183	0.00267	CcSEcCtD
Paroxetine—Flatulence—Varenicline—nicotine dependence	0.0018	0.00263	CcSEcCtD
Paroxetine—Dysgeusia—Varenicline—nicotine dependence	0.00179	0.00262	CcSEcCtD
Paroxetine—Back pain—Varenicline—nicotine dependence	0.00177	0.00258	CcSEcCtD
Paroxetine—Muscle spasms—Varenicline—nicotine dependence	0.00176	0.00257	CcSEcCtD
Paroxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00175	0.0063	CbGpPWpGaD
Paroxetine—CYP2B6—cardiovascular system—nicotine dependence	0.00174	0.0474	CbGeAlD
Paroxetine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00173	0.00625	CbGpPWpGaD
Paroxetine—CYP2C8—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00173	0.00622	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00173	0.00622	CbGpPWpGaD
Paroxetine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00173	0.00622	CbGpPWpGaD
Paroxetine—Vision blurred—Varenicline—nicotine dependence	0.00173	0.00252	CcSEcCtD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.00172	0.0062	CbGpPWpGaD
Paroxetine—CYP2C9—cardiovascular system—nicotine dependence	0.00172	0.047	CbGeAlD
Paroxetine—Tremor—Varenicline—nicotine dependence	0.00172	0.0025	CcSEcCtD
Paroxetine—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00171	0.00616	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—FGD1—nicotine dependence	0.0017	0.00614	CbGpPWpGaD
Paroxetine—Ill-defined disorder—Varenicline—nicotine dependence	0.0017	0.00248	CcSEcCtD
Paroxetine—Anaemia—Varenicline—nicotine dependence	0.00169	0.00247	CcSEcCtD
Paroxetine—TACR1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00169	0.00608	CbGpPWpGaD
Paroxetine—Agitation—Varenicline—nicotine dependence	0.00168	0.00245	CcSEcCtD
Paroxetine—Angioedema—Varenicline—nicotine dependence	0.00167	0.00244	CcSEcCtD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00165	0.00596	CbGpPWpGaD
Paroxetine—Malaise—Varenicline—nicotine dependence	0.00165	0.00241	CcSEcCtD
Paroxetine—Vertigo—Varenicline—nicotine dependence	0.00165	0.0024	CcSEcCtD
Paroxetine—Syncope—Varenicline—nicotine dependence	0.00164	0.00239	CcSEcCtD
Paroxetine—Palpitations—Varenicline—nicotine dependence	0.00162	0.00236	CcSEcCtD
Paroxetine—Loss of consciousness—Varenicline—nicotine dependence	0.00161	0.00235	CcSEcCtD
Paroxetine—Cough—Varenicline—nicotine dependence	0.0016	0.00233	CcSEcCtD
Paroxetine—SLC6A3—Neuronal System—CHRNB3—nicotine dependence	0.00159	0.00574	CbGpPWpGaD
Paroxetine—CHRM4—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00159	0.00574	CbGpPWpGaD
Paroxetine—Convulsion—Varenicline—nicotine dependence	0.00159	0.00231	CcSEcCtD
Paroxetine—Hypertension—Varenicline—nicotine dependence	0.00158	0.00231	CcSEcCtD
Paroxetine—Arthralgia—Varenicline—nicotine dependence	0.00156	0.00227	CcSEcCtD
Paroxetine—Chest pain—Varenicline—nicotine dependence	0.00156	0.00227	CcSEcCtD
Paroxetine—Myalgia—Varenicline—nicotine dependence	0.00156	0.00227	CcSEcCtD
Paroxetine—Anxiety—Varenicline—nicotine dependence	0.00155	0.00227	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00155	0.00226	CcSEcCtD
Paroxetine—Discomfort—Varenicline—nicotine dependence	0.00154	0.00225	CcSEcCtD
Paroxetine—TACR1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00153	0.00552	CbGpPWpGaD
Paroxetine—CHRM4—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00153	0.0055	CbGpPWpGaD
Paroxetine—CHRM5—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00153	0.0055	CbGpPWpGaD
Paroxetine—Dry mouth—Varenicline—nicotine dependence	0.00152	0.00222	CcSEcCtD
Paroxetine—SLC6A3—Neuronal System—CHRNA6—nicotine dependence	0.00151	0.00544	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00151	0.00543	CbGpPWpGaD
Paroxetine—Oedema—Varenicline—nicotine dependence	0.00149	0.00218	CcSEcCtD
Paroxetine—Infection—Varenicline—nicotine dependence	0.00148	0.00217	CcSEcCtD
Paroxetine—Shock—Varenicline—nicotine dependence	0.00147	0.00214	CcSEcCtD
Paroxetine—Nervous system disorder—Varenicline—nicotine dependence	0.00147	0.00214	CcSEcCtD
Paroxetine—Thrombocytopenia—Varenicline—nicotine dependence	0.00146	0.00213	CcSEcCtD
Paroxetine—CHRM5—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00146	0.00527	CbGpPWpGaD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00146	0.00526	CbGpPWpGaD
Paroxetine—Tachycardia—Varenicline—nicotine dependence	0.00146	0.00213	CcSEcCtD
Paroxetine—Skin disorder—Varenicline—nicotine dependence	0.00145	0.00212	CcSEcCtD
Paroxetine—Hyperhidrosis—Varenicline—nicotine dependence	0.00144	0.00211	CcSEcCtD
Paroxetine—CHRM2—brain—nicotine dependence	0.00144	0.0392	CbGeAlD
Paroxetine—SLC6A3—brain—nicotine dependence	0.00143	0.0391	CbGeAlD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00143	0.00513	CbGpPWpGaD
Paroxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00142	0.00511	CbGpPWpGaD
Paroxetine—HTR2A—cardiovascular system—nicotine dependence	0.00142	0.0387	CbGeAlD
Paroxetine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00141	0.00506	CbGpPWpGaD
Paroxetine—Hypotension—Varenicline—nicotine dependence	0.0014	0.00204	CcSEcCtD
Paroxetine—CHRM4—GPCR ligand binding—TAS2R16—nicotine dependence	0.00137	0.00494	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00137	0.00492	CbGpPWpGaD
Paroxetine—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00136	0.00199	CcSEcCtD
Paroxetine—Insomnia—Varenicline—nicotine dependence	0.00135	0.00197	CcSEcCtD
Paroxetine—Dyspnoea—Varenicline—nicotine dependence	0.00133	0.00194	CcSEcCtD
Paroxetine—Somnolence—Varenicline—nicotine dependence	0.00133	0.00194	CcSEcCtD
Paroxetine—SLC6A4—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00133	0.00478	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—FGD1—nicotine dependence	0.00133	0.00477	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00132	0.00474	CbGpPWpGaD
Paroxetine—Dyspepsia—Varenicline—nicotine dependence	0.00132	0.00192	CcSEcCtD
Paroxetine—CHRM5—GPCR ligand binding—TAS2R16—nicotine dependence	0.00131	0.00473	CbGpPWpGaD
Paroxetine—SLC6A4—brain—nicotine dependence	0.00131	0.0359	CbGeAlD
Paroxetine—CHRM1—brain—nicotine dependence	0.00131	0.0357	CbGeAlD
Paroxetine—Decreased appetite—Varenicline—nicotine dependence	0.0013	0.00189	CcSEcCtD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00129	0.00466	CbGpPWpGaD
Paroxetine—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00129	0.00188	CcSEcCtD
Paroxetine—Fatigue—Varenicline—nicotine dependence	0.00129	0.00188	CcSEcCtD
Paroxetine—Pain—Varenicline—nicotine dependence	0.00128	0.00186	CcSEcCtD
Paroxetine—Constipation—Varenicline—nicotine dependence	0.00128	0.00186	CcSEcCtD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00127	0.00458	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—OPRM1—nicotine dependence	0.00126	0.00454	CbGpPWpGaD
Paroxetine—Feeling abnormal—Varenicline—nicotine dependence	0.00123	0.0018	CcSEcCtD
Paroxetine—Gastrointestinal pain—Varenicline—nicotine dependence	0.00122	0.00178	CcSEcCtD
Paroxetine—TACR1—Signaling by GPCR—FGD1—nicotine dependence	0.0012	0.00433	CbGpPWpGaD
Paroxetine—TACR1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.0012	0.00431	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—CHRNB2—nicotine dependence	0.00119	0.00429	CbGpPWpGaD
Paroxetine—Urticaria—Varenicline—nicotine dependence	0.00119	0.00173	CcSEcCtD
Paroxetine—Abdominal pain—Varenicline—nicotine dependence	0.00118	0.00172	CcSEcCtD
Paroxetine—Body temperature increased—Varenicline—nicotine dependence	0.00118	0.00172	CcSEcCtD
Paroxetine—CHRM3—brain—nicotine dependence	0.00117	0.032	CbGeAlD
Paroxetine—SLC6A2—brain—nicotine dependence	0.00116	0.0316	CbGeAlD
Paroxetine—CYP2B6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00115	0.00414	CbGpPWpGaD
Paroxetine—HTR2A—midbrain—nicotine dependence	0.00111	0.0302	CbGeAlD
Paroxetine—Hypersensitivity—Varenicline—nicotine dependence	0.0011	0.00161	CcSEcCtD
Paroxetine—SLC6A3—Neuronal System—GABRA4—nicotine dependence	0.00109	0.00393	CbGpPWpGaD
Paroxetine—CYP2B6—Biological oxidations—CYP2A7—nicotine dependence	0.00108	0.0039	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00107	0.00387	CbGpPWpGaD
Paroxetine—Asthenia—Varenicline—nicotine dependence	0.00107	0.00156	CcSEcCtD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00107	0.00386	CbGpPWpGaD
Paroxetine—CYP2B6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00107	0.00385	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—WASF2—nicotine dependence	0.00106	0.00382	CbGpPWpGaD
Paroxetine—Pruritus—Varenicline—nicotine dependence	0.00106	0.00154	CcSEcCtD
Paroxetine—SLC6A3—Neuronal System—CHRNB4—nicotine dependence	0.00105	0.00377	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00104	0.00373	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00103	0.00371	CbGpPWpGaD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00103	0.0037	CbGpPWpGaD
Paroxetine—Diarrhoea—Varenicline—nicotine dependence	0.00102	0.00149	CcSEcCtD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—WASF1—nicotine dependence	0.00102	0.00366	CbGpPWpGaD
Paroxetine—Dizziness—Varenicline—nicotine dependence	0.000988	0.00144	CcSEcCtD
Paroxetine—CYP2C8—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000973	0.00351	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—CHRNA5—nicotine dependence	0.000973	0.00351	CbGpPWpGaD
Paroxetine—CHRM4—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000955	0.00344	CbGpPWpGaD
Paroxetine—Vomiting—Varenicline—nicotine dependence	0.00095	0.00139	CcSEcCtD
Paroxetine—CYP2C8—brain—nicotine dependence	0.00095	0.0259	CbGeAlD
Paroxetine—Rash—Varenicline—nicotine dependence	0.000942	0.00137	CcSEcCtD
Paroxetine—Dermatitis—Varenicline—nicotine dependence	0.000941	0.00137	CcSEcCtD
Paroxetine—Headache—Varenicline—nicotine dependence	0.000936	0.00137	CcSEcCtD
Paroxetine—HTR2A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00093	0.00335	CbGpPWpGaD
Paroxetine—ABCB1—cardiovascular system—nicotine dependence	0.000928	0.0253	CbGeAlD
Paroxetine—CHRM1—GPCR ligand binding—TAS2R16—nicotine dependence	0.000925	0.00333	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—TAS2R16—nicotine dependence	0.000922	0.00332	CbGpPWpGaD
Paroxetine—CYP2C8—Biological oxidations—CYP2A7—nicotine dependence	0.000918	0.0033	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—TAS2R16—nicotine dependence	0.000913	0.00329	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.000912	0.00328	CbGpPWpGaD
Paroxetine—TACR1—GPCR ligand binding—DRD2—nicotine dependence	0.000911	0.00328	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TAS2R16—nicotine dependence	0.000906	0.00326	CbGpPWpGaD
Paroxetine—CYP2C8—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000905	0.00326	CbGpPWpGaD
Paroxetine—Nausea—Varenicline—nicotine dependence	0.000888	0.00129	CcSEcCtD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000887	0.00319	CbGpPWpGaD
Paroxetine—SLC6A4—Circadian rythm related genes—DRD2—nicotine dependence	0.000881	0.00317	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000879	0.00317	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.000863	0.00311	CbGpPWpGaD
Paroxetine—CYP2B6—brain—nicotine dependence	0.000852	0.0233	CbGeAlD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000849	0.00306	CbGpPWpGaD
Paroxetine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.000828	0.00298	CbGpPWpGaD
Paroxetine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000799	0.00288	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000798	0.00287	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—CHRNA3—nicotine dependence	0.000794	0.00286	CbGpPWpGaD
Paroxetine—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000792	0.00285	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.000784	0.00282	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000775	0.00279	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00076	0.00274	CbGpPWpGaD
Paroxetine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.000753	0.00271	CbGpPWpGaD
Paroxetine—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.000747	0.00269	CbGpPWpGaD
Paroxetine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000743	0.00268	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000743	0.00267	CbGpPWpGaD
Paroxetine—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000737	0.00265	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000727	0.00262	CbGpPWpGaD
Paroxetine—ABCB1—midbrain—nicotine dependence	0.000725	0.0198	CbGeAlD
Paroxetine—CHRM1—Circadian rythm related genes—CHRNB2—nicotine dependence	0.000714	0.00257	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—OPRM1—nicotine dependence	0.000712	0.00256	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—FGD1—nicotine dependence	0.000711	0.00256	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—TAS2R16—nicotine dependence	0.000704	0.00254	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—CHRNB2—nicotine dependence	0.000699	0.00252	CbGpPWpGaD
Paroxetine—HTR2A—brain—nicotine dependence	0.000695	0.019	CbGeAlD
Paroxetine—CHRM4—G alpha (i) signalling events—DRD2—nicotine dependence	0.000691	0.00249	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—TAS2R16—nicotine dependence	0.000674	0.00243	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000663	0.00239	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—OPRM1—nicotine dependence	0.000646	0.00233	CbGpPWpGaD
Paroxetine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000641	0.00231	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—OPRM1—nicotine dependence	0.000636	0.00229	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—CHRNA4—nicotine dependence	0.000634	0.00228	CbGpPWpGaD
Paroxetine—CYP2D6—brain—nicotine dependence	0.000633	0.0173	CbGeAlD
Paroxetine—TACR1—Signaling Pathways—AKR1B10—nicotine dependence	0.000628	0.00226	CbGpPWpGaD
Paroxetine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000614	0.00221	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—FGD1—nicotine dependence	0.000608	0.00219	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000601	0.00216	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000598	0.00215	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.000596	0.00215	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00059	0.00213	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000587	0.00211	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—FGD1—nicotine dependence	0.000583	0.0021	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—OPRM1—nicotine dependence	0.000578	0.00208	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—OPRM1—nicotine dependence	0.000554	0.00199	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—FGD1—nicotine dependence	0.000553	0.00199	CbGpPWpGaD
Paroxetine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000549	0.00198	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—FGD1—nicotine dependence	0.000529	0.00191	CbGpPWpGaD
Paroxetine—CHRM1—Circadian rythm related genes—DRD2—nicotine dependence	0.000528	0.0019	CbGpPWpGaD
Paroxetine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000526	0.00189	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000526	0.00189	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000523	0.00188	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000521	0.00188	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000516	0.00186	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000515	0.00185	CbGpPWpGaD
Paroxetine—TACR1—GPCR downstream signaling—DRD2—nicotine dependence	0.000515	0.00185	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000512	0.00184	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000511	0.00184	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000506	0.00182	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000477	0.00172	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—TAS2R16—nicotine dependence	0.000475	0.00171	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—TAS2R16—nicotine dependence	0.000473	0.0017	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—TAS2R16—nicotine dependence	0.000469	0.00169	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—DRD2—nicotine dependence	0.000467	0.00168	CbGpPWpGaD
Paroxetine—CHRM2—G alpha (i) signalling events—DRD2—nicotine dependence	0.00046	0.00166	CbGpPWpGaD
Paroxetine—ABCB1—brain—nicotine dependence	0.000455	0.0124	CbGeAlD
Paroxetine—TACR1—Signaling Pathways—WASF2—nicotine dependence	0.000442	0.00159	CbGpPWpGaD
Paroxetine—HTR2A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000435	0.00156	CbGpPWpGaD
Paroxetine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000432	0.00156	CbGpPWpGaD
Paroxetine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000431	0.00155	CbGpPWpGaD
Paroxetine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000427	0.00154	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—WASF1—nicotine dependence	0.000424	0.00153	CbGpPWpGaD
Paroxetine—CHRM4—GPCR ligand binding—DRD2—nicotine dependence	0.000418	0.00151	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TAS2R16—nicotine dependence	0.000416	0.0015	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—FGD1—nicotine dependence	0.000412	0.00149	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—FGD1—nicotine dependence	0.00041	0.00148	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—FGD1—nicotine dependence	0.000409	0.00147	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—FGD1—nicotine dependence	0.000405	0.00146	CbGpPWpGaD
Paroxetine—CHRM5—GPCR ligand binding—DRD2—nicotine dependence	0.0004	0.00144	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TAS2R16—nicotine dependence	0.000398	0.00143	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—OPRM1—nicotine dependence	0.000392	0.00141	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—OPRM1—nicotine dependence	0.00039	0.0014	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—OPRM1—nicotine dependence	0.000389	0.0014	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—OPRM1—nicotine dependence	0.000385	0.00139	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—OPRM1—nicotine dependence	0.000382	0.00138	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—FGD1—nicotine dependence	0.000375	0.00135	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—FGD1—nicotine dependence	0.000373	0.00134	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000372	0.00134	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—FGD1—nicotine dependence	0.000371	0.00134	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00037	0.00133	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000369	0.00133	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—FGD1—nicotine dependence	0.000368	0.00132	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000366	0.00132	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—OPRM1—nicotine dependence	0.000327	0.00118	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—FGD1—nicotine dependence	0.000326	0.00118	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—OPRM1—nicotine dependence	0.000313	0.00113	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—FGD1—nicotine dependence	0.000313	0.00113	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—OPRM1—nicotine dependence	0.000297	0.00107	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.000292	0.00105	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKR1B10—nicotine dependence	0.000288	0.00104	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—OPRM1—nicotine dependence	0.000284	0.00102	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—DRD2—nicotine dependence	0.000283	0.00102	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TAS2R16—nicotine dependence	0.000282	0.00102	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—DRD2—nicotine dependence	0.000282	0.00102	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—DRD2—nicotine dependence	0.000281	0.00101	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TAS2R16—nicotine dependence	0.00028	0.00101	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TAS2R16—nicotine dependence	0.00028	0.00101	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—DRD2—nicotine dependence	0.000278	0.001	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TAS2R16—nicotine dependence	0.000277	0.000997	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKR1B10—nicotine dependence	0.000276	0.000994	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—DRD2—nicotine dependence	0.000276	0.000994	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—DRD2—nicotine dependence	0.000236	0.000851	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—DRD2—nicotine dependence	0.000226	0.000815	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000222	0.000798	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGD1—nicotine dependence	0.000221	0.000797	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—OPRM1—nicotine dependence	0.00022	0.000794	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGD1—nicotine dependence	0.00022	0.000793	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—OPRM1—nicotine dependence	0.00022	0.000791	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGD1—nicotine dependence	0.000219	0.00079	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—OPRM1—nicotine dependence	0.000218	0.000784	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGD1—nicotine dependence	0.000217	0.000782	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP2A7—nicotine dependence	0.000215	0.000776	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—DRD2—nicotine dependence	0.000215	0.000773	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—DRD2—nicotine dependence	0.000206	0.00074	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—WASF2—nicotine dependence	0.000203	0.000732	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—OPRM1—nicotine dependence	0.000201	0.000725	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—OPRM1—nicotine dependence	0.0002	0.000721	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—OPRM1—nicotine dependence	0.0002	0.000719	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—OPRM1—nicotine dependence	0.000198	0.000712	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKR1B10—nicotine dependence	0.000195	0.000704	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—WASF1—nicotine dependence	0.000195	0.000701	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—WASF2—nicotine dependence	0.000195	0.000701	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKR1B10—nicotine dependence	0.000194	0.0007	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKR1B10—nicotine dependence	0.000194	0.000698	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKR1B10—nicotine dependence	0.000192	0.000691	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—WASF1—nicotine dependence	0.000187	0.000672	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP2A7—nicotine dependence	0.000185	0.000668	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—OPRM1—nicotine dependence	0.000175	0.000632	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—OPRM1—nicotine dependence	0.000168	0.000605	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—DRD2—nicotine dependence	0.00016	0.000577	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—DRD2—nicotine dependence	0.000159	0.000574	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—DRD2—nicotine dependence	0.000159	0.000572	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—DRD2—nicotine dependence	0.000157	0.000567	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP2A7—nicotine dependence	0.000157	0.000565	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—DRD2—nicotine dependence	0.000145	0.000524	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—DRD2—nicotine dependence	0.000145	0.000521	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—DRD2—nicotine dependence	0.000144	0.00052	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—DRD2—nicotine dependence	0.000143	0.000514	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—WASF2—nicotine dependence	0.000138	0.000496	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—WASF2—nicotine dependence	0.000137	0.000493	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP2A7—nicotine dependence	0.000137	0.000492	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—WASF2—nicotine dependence	0.000137	0.000492	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—WASF2—nicotine dependence	0.000135	0.000487	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—WASF1—nicotine dependence	0.000132	0.000475	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—WASF1—nicotine dependence	0.000131	0.000473	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—WASF1—nicotine dependence	0.000131	0.000471	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—WASF1—nicotine dependence	0.00013	0.000467	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000129	0.000464	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000128	0.00046	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—DRD2—nicotine dependence	0.000127	0.000457	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—DRD2—nicotine dependence	0.000121	0.000437	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—OPRM1—nicotine dependence	0.000119	0.000428	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—OPRM1—nicotine dependence	0.000118	0.000426	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—OPRM1—nicotine dependence	0.000118	0.000424	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—OPRM1—nicotine dependence	0.000117	0.00042	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DRD2—nicotine dependence	8.59e-05	0.00031	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DRD2—nicotine dependence	8.55e-05	0.000308	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DRD2—nicotine dependence	8.52e-05	0.000307	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DRD2—nicotine dependence	8.44e-05	0.000304	CbGpPWpGaD
